ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Score Distribution, Other Charts, On P01s

October 2, 1992

Final Regulations For Clinical Cancer Education Program Adopted

October 3, 1975

NCI Advisors Approve Expansion Of CCOPs, Minority-Based CCOPs; Approve Reissuance Of BMT Network RFA, RFPs For Preclinical Drug Studies

November 13, 2009

Minority Trial Participation A Matter of Access, Study Says

December 30, 2005

NCI Sends A Second Letter To Groups About Carboplatin

October 22, 2010

Neutron Therapy “Treatment Of Choice” In Salivary Gland Tumors – 100 Percent Complete Reponses

June 13, 1986